Právní předpis byl sestaven k datu 19.12.2013.
Zobrazené znění právního předpisu je účinné od 25.12.2012 do 19.12.2013.
97
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx mění x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx věcí x. 58/2007 Xx. x. s., č. 46/2008 Sb. x. x. x č. 47/2012 Sb. x. x. x Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, že dne 16. xxxxxxxxx 2011 xxxx generální xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Přílohy X - Seznamu xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx ve xxxxxx.1)
X novým xxxxxx Xxxxxxx I xxxxxxxx souhlas Xxxxxxxxx Xxxxx xxxxxxxxx.
Nové xxxxx Xxxxxxx I xxxxxxxxx x platnost x xxxxxxx x xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2012 x tímto xxxx xxxxxxxxx x xxxxxxxx x xxx Českou xxxxxxxxx. Xxxx xxxxxx xxxxxx xxxxx Xxxxxxx X v xxxxxxxx xxxxxxxx xxxxxx znění Xxxxxxx I Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu xxxxxx xx 1. xxxxx 2011 x xxxxxxxxx xxx č. 47/2012 Sb. m. s.
Anglické xxxxx Přílohy X x xxxx xxxxxxx xx českého xxxxxx xx xxxxxxxxx současně.
1) Mezinárodní xxxxxx xxxxx dopingu xx xxxxxx přijatá xxx 19. xxxxx 2005 v Xxxxxx xxxx xxxxxxxxx pod č. 58/2007 Sb. m. s.
XXXXXXXXXXX XXXXXX PROTI DOPINGU XX XXXXXX
Příloha X - Xxxxxx xxxxxxxxxx xxxxx a xxxxx - Mezinárodní xxxxxxxx
Paříž, 1. xxxxx 2012
SEZNAM XXXXXXXXXX XXXXX A XXXXX XXXXXXX PRO XXX 2012
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx xx 1. xxxxx 2012
Xxxxx xxxxxx 4.2.2 Xxxxxxxxx antidopingového xxxxxx xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx látky" xxxxx xxxxx xx xxxxxx X1, X2, X4.4, X4.5 x X6(x) x Zakázaných xxxxx X1, M2 x M3.
XXXXX X XXXXXX XXXXXXXX XXXXX (PŘI SOUTĚŽI X MIMO XXXXXX) |
XXXXXXXX LÁTKY
X0. XXXXXXXXXXX XXXXX
Jakákoliv xxxxxxxxxxxxx látka, která xxxx zahrnuta x xxxxxxxxxxxxx xxxxxxx Seznamu x xxxx aktuálně xxxxxxxxx pro xxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (např. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, syntetické xxxxx, xxxxxxxxxxx xxxx), xx xxxxxxxx xxxxx.
X1. XXXXXXXXXX XXXXX
Anabolické xxxxx xxxx xxxxxxxx.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):
(x) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-androstendion (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; boldenon; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; ethylestrenol (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; formebolon; xxxxxxxxx (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-hydroxy-17α-methyl-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); miboleron; xxxxxxxxx; 19-norandrostendion (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; norklostebol; xxxxxxxx; oxandrolon; oxymesteron; xxxxxxxxxx; prostanozol (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-hydroxy-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxx (18α-homo-pregna-4,9,11-trien-17β-ol-3-on); trenbolon x další xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.
(b) Xxxxxxxxx** AAS, xxxxx xxxx xxxxxx xxxxxxxx:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX), testosteron x xxxxxx metabolity x xxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně:
5α-xxxxxxxxx-3α,17α-xxxx | 5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx) |
5α-xxxxxxxxx-3α,17β-xxxx | |
5α-xxxxxxxxx-3β,17α-xxxx | xxx-xxxxxxxxxxxxxxxxxx |
5α-xxxxxxxxx-3β,17β-xxxx | epitestosteron |
xxxxxxx-4-xx-3α,17α-xxxx | 3α-hydroxy-5αandrostan-17-on |
xxxxxxx-4-xx-3α,17β-xxxx | 3β-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-5-xx-3β,17α-xxxx | 7α-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17α-xxxx | 7β-hydroxy-DHEA |
xxxxxxx-5-xx-3α,17β-xxxX | 7-xxxx-XXXX |
xxxxxxx-5-xx-3β,17α-xxxx | 19-norandrosteron |
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx) | 19-noretiocholanolon |
2. Xxxxxxx xxxxxxxxxx xxxxx, zahrnující:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), tibolon, xxxxxxx, xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.
Xxx xxxxx xxxxxxx xxxx xxxxx: * "xxxxxxxx" se vztahuje x látce, kterou xxxx není normálně xxxxxxx produkovat xxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx k xxxxx, xxxxxx xxxx xxxx xxxxxxxxxx xxxxxxxxx. |
X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX X XXXXXXXX XXXXX
Xxxxxxxxxxx xxxxx a xxxxxx xxxxxxxxxx faktory xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx erytropoesu (xxxx. xxxxxxxxxxxx (XXX), xxxxxxxxxxx (dEPO), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx beta (XXXX), xxxxxxxxxxx /Xxxxxxxx/);
2. Xxxxxxxxxxxxxxxxxx (XX) x Xxxxxxxxxxxx xxxxxx (XX) x xxxx;
3. Xxxxxxxx;
4. Xxxxxxxxxxxxxx;
5. Xxxxxxx xxxxxx (XX), xxxxxxxxxxxxx xxxxxxx xxxxxxx (FGFs), xxxxxxxxxxxx xxxxxxx faktor (XXX), insulinu podobný xxxxxxx xxxxxx-1 (XXX-1), xxxxxxxxxx xxxxxxx faktory (XXX), růstový xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), stejně xxxx xxxxxxxxx jiné růstové xxxxxxx ovlivňující xxxxxxx xxxx xxxxxxxxx bílkovin xxxxx, šlach a xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových vláken;
x další xxxxx x xxxxxxxx chemickou xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx.
S3. XXXX2- XXXXXXXX
Xxxxxxx xxxx-2 xxxxxxxx (xxxxxx xxxx případných xxxxxxxxx xxxxxxx) xxxx xxxxxxxx xxxxx xxxxxxxxxxx (xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx), formoterolu (xxxxxxxxx 36 xxxxxxxxxx xx 24 xxxxx) x xxxxxxxxxxx xxxxx xxxx podány v xxxxxxxx x xxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx xxxxxxxxxxx x moči x koncentraci xxxxx xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x moči v xxxxxxxxxxx vyšší xxx 30 xx/xx xxxxxx xxxxxxxxxx za xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx způsoben xxxxxxxx xxxxxxxxxxxx inhalační xxxxx xxxxx xxx výše xxxxxxx xxxxxxx.
X4. XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX
Zakázané xx xxxxxxxxxxx:
1. Inhibitory xxxxxxxx, zahrnující:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-oxo),exemestan, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx s omezením xxxxx na xx.
2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX), xxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, ale xx x xxxxxxxx pouze xx ně.
3. Xxxxxxx antiestrogenní xxxxx xxxxxxxxxx:
Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxx xx x xxxxxxxx pouze xx xx.
4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxx xx x omezením xxxxx xx ně.
5. Xxxxxxxxxxx xxxxxxxxxx: Xxxxxxxx xxxxx aktivovaný xxxxxxxxxxxxxx xxxxxxxxxxxxx /Peroxisome Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (XXXXδ) xxxxxxxx/ (xxxx. GW 1516) x Xxxxxxxx proteinkinasové xxx aktivované AMP x xxxxxxxxxxx s XXXX delta /XXXXδ-XXX-xxxxxxxxx xxxxxxx xxxxxx (AMPK) xxxx xxxxxxxx/ (např. XXXXX)
S5. XXXXXXXXX X XXXXXXX XXXXXXXXX XXXXX
Maskovací látky xxxx xxxxxxxx. Zahrnují:
Xxxxxxxxx, desmopressin, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, nitrožilní xxxxxx albuminu, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx a další xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxxxx felypressinu xxx xxxxx xxxxxxxx není xxxxxxxx.
Diuretika xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, bumetanid, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxxxx a xxxxxxxxxxxx, které xxxxxx xxxxxxxx).
Pro xxxxxxx (Xxx Xxxxxxx, případně Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx látky xx xxxxxxxxxx xxxxxxxx limitem (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx xxxxxxx s xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx na xxxx látku xxxxx x xx, která xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx maskovací xxxxx.
XXXXXXXX METODY
X1. XXXXXXXXX PŘENOSU XXXXXXX
Xxxxxxxx xx následující:
1. Krevní xxxxxx, xxxxxx xxxxxxx xxxxxxxxx, xxxxxxxxx nebo xxxxxxxxxxx xxxx nebo xxxxxxxxx xxxxxxx x jim xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx.
2. Umělé xxxxxxxxx xxxxxxxx, přenosu xxxx dodávky xxxxxxx, xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx.xxxxxx xxxxxxxx xxxxxxxx na xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x efaproxiral (RSR13), xxx xx x xxxxxxxx xxxxx xx xx. Xxxxxxxx xxxxxxx xxxxxxxx xxxx.
X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
1. Xxxxxxxxx, xxxx pokus x xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx a xxxxxxxx Vzorků xxxxxxxxxx xxx Xxxxxxxxx kontrole xx zakázané. Xx xxxxxxxx xxxxxx a/nebo xxxxxx (xxxx. xxxxxxxxxx) xxxx, xxx ne x xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxx 50 ml xx 6 xxxxx xxxx xxxxxxxx kromě xxxxxx xxxxxxxxx xxxxxxxxx v xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx klinických vyšetřovacích xxxxx.
3. Postupný xxxxx, xxxxxxxxxx x xxxxxxxxx jakéhokoliv množství xxxx krve do xxxxxxxxx xxxxxxx xx xxxxxxxx.
X3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:
1. Xxxxxxxx xxxxxxxxxx kyselin xxxx xxxxxx xxxxxxxx;
2. Použití xxxxxxxxxx xxxx xxxxxxxxx modifikovaných xxxxx;
XXXXX X XXXXXX XXXXXXXX XXX XXXXXXX |
Xxxxx xxxxxxxxx SO xx S5 x X1 až X3 xxxxxxxxx xxxx xxxx Xxx Soutěži xxxxxxxx x následující xxxxxxx:
XXXXXXXX XXXXX
S6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx (xxxxxx xxxx xxxxxx xxxxxxxxxx xxxxxxxxx isomerů) xxxx xxxxxxxx, x xxxxxxxx xxxxxxxx xxxxxxxxx x případě xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2012*.
Stimulancia xxxxxxxx:
(a) Nespecifická xxxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, amfetamin, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, benzylpiperazin, xxxxxxxxx, xxxxxxxxxxxxxxxxx, ethylamfetamin, xxxxxxxxxxx, xxxxxxxxxxxxx, fenetylin, xxxxxxxxxxx, xxxxxxxx, fenmetrazin, xxxxxxxxxxx, fentermin, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, klobenzorex, xxxxxx, xxxxxxxxxxx, krotetamid, xxxxxxxxx, mefentermin, metamfetamin (x-), xxxxxxxxxxxxxxxxxxxxxx, methylendioxymetamfetamin, xxxxxxxx, modafinil, norfenfluramin, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx.
Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx v xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxxx xxxxxxxxxxx (xxxxxxxx):
Xxxxxxxxx**, katin***, xxxxxxx****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, heptaminol, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, meklofenoxát, xxxxxxxxxxxx****, methylfenidát, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, sibutramin, xxxxxxxxx, xxxxxxxxxxxxx x další xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx.
* Následující xxxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2012 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, pipradrol, synefrin) xxxxxx považovány za Xxxxxxxx látky.
** Xxxxxxx xxxxxx adrenalinu (xxxx. xxxxx, oční xxxxxxxx) xxxx jeho xxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx není xxxxxxxx.
*** Xxxxx xx xxxxxxxx pouze xxx koncentraci xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.
**** Efedrin x xxxxxxxxxxxxx xxxx xxxxxxxx při xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx v 1 xx xxxx.
***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx jeho xxxxxxxxxxx x moči xx xxxxx xxx 150 xxxxxxxxxx na xxxxxxxx
X7. XXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
Buprenorfin, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x xxxx xxxxxxxx, xxxxxxxxxxx, metadon, xxxxxx, xxxxxxxx, xxxxxxxxx, pentazocin, xxxxxxx.
X8. XXXXXXXXXXX
Xxxxxxxx (xxxx. xxxxx, xxxxxx x xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9xxxxxxxxxxxxxxxxxxx (XXX) a xxxxxxxxxxxxxx (xxxx. "Xxxxx" /obsahující XXX018, JWH073/ x XX-210) xxxx xxxxxxxx.
X9. GLUKOKORTIKOSTEROIDY
Xxxxxxx xxxxxxxxxxxxxxxxxxxx podávané orálně, xxxxxxxx, xxxxxxxxxx nebo xxxxxxxxxxxxx aplikací xxxx xxxxxxxx.
LÁTKY XXXXXXXX X XXXXXXXX XXXXXXXX |
X1. XXXXXXX
Xxxxxxx (xxxxxx) xx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx bude xxxxxxxx xxxxxxxx zkouškou x/xxxx xxxxxxxx xxxx. Xxxxxxx xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) xx 0.10 x/x.
∙ Automobilový xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx sporty x xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (XXXX)
∙ Motocyklový xxxxx (FIM)
∙ Xxxxx xxxxxxxxxx (XXX)
X2. BETA-BLOKÁTORY
Xxxxx xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx zakázány xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Billiard (xxxxxxx discipliny) (XXXX)
∙ Xxxxx (XXX)
∙ Xxxx (XXX)
∙ Kuželky x xxxxxxx (XXX)
∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx (XXX)
∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Mimo xxxxxx)
∙ Lyžování (XXX) - xxxxx xx lyžích a xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx,x snowboard X-xxxxx x "xxx xxx"
∙ Petanque a xxxxxxx xxxxxx (XXXX)
∙ Střelba (XXXX, XXX) (xxxxxxxx xxxx Xxxx soutěž)
∙ Xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XxX)
Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:
Acebutolol, xxxxxxxxxx, xxxxxxxx, betaxolol, bisoprolol, xxxxxxx, xxxxxxxxxx, esmolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, sotalol, xxxxxxx, xxx ne x xxxxxxxx xxxxx xx xx.
Informace
Xxxxxx xxxxxxx č. 97/2012 Xx. x. x. xxxxx xxxxxxxxx xxxx 25.12.2012.
Xxxxxx xxxxxxx x. 97/2012 Sb. m. x. byl xxxxxx xxxxxxx xxxxxxxxx č. 98/2013 Sb. m. s. x účinností xx 20.12.2013.
Xxxxx xxxxxxxxxxxx právních xxxxx xxxxxx xxxxxxxx předpisů x xxxxxxxx není xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx předpisu.